Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

SAB4503996

Sigma-Aldrich

Anti-phospho-Synuclein (pSer129) antibody produced in rabbit

affinity isolated antibody

Synonyme(s) :

Anti-NACP, Anti-PARK1, Anti-PARK4, Anti-PD1

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

rabbit

Niveau de qualité

100

Conjugué

unconjugated

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

primary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Poids mol.

antigen 14 kDa

Espèces réactives

mouse, rat, human

Concentration

~1 mg/mL

Technique(s)

ELISA: 1:1000
immunohistochemistry: 1:50-1:100
western blot: 1:500-1:1000

Numéro d'accès NCBI

P37840

Numéro d'accès UniProt

P37840

Conditions d'expédition

wet ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

phosphorylation (pSer129)

Informations sur le gène

human ... SNCA(6622)

Description générale

The SNCA (synuclein α) gene codes for a 140-amino acid protein α-synuclein, that is mapped to human chromosome 4q21-23.

Immunogène

The antiserum was produced against synthesized peptide derived from human Synuclein around the phosphorylation site of Ser129.

Immunogen Range: 91-140

Application

Anti-phospho-Synuclein (pSer129) antibody has been used in immunohistochemistry.

Actions biochimiques/physiologiques

Accumulation of α-synuclein in oligodendrocytes results in the loss of myelin and causes neurodegeneration, leading to multiple system atrophy. Synuclein-α is known to induce oligodendrocyte maturation. Mutations in the SNCA result in parkinson disease.

Caractéristiques et avantages

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Forme physique

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Guadalupe Vidal-Martínez et al.
The Journal of biological chemistry, 291(39), 20811-20821 (2016-08-17)
Patients with Parkinson's disease (PD) often have aggregated α-synuclein (aSyn) in enteric nervous system (ENS) neurons, which may be associated with the development of constipation. This occurs well before the onset of classic PD motor symptoms. We previously found that
FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF
Vidal-Martinez G, et al.
The Journal of Biological Chemistry, 291(39), 20811-20821 (2016)
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy
Kiely AP, et al.
Acta Neuropathologica, 125(5), 753-769 (2013)
Guadalupe Vidal-Martinez et al.
Experimental neurology, 325, 113120-113120 (2019-11-22)
Multiple system atrophy (MSA) is a fatal disorder with no effective treatment. MSA pathology is characterized by α-synuclein (aSyn) accumulation in oligodendrocytes, the myelinating glial cells of the central nervous system (CNS). aSyn accumulation in oligodendrocytes forms the pathognomonic glial
?-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy.
Ettle B
Acta Neuropathologica, 132(1), 59-75 (2016)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique